PCN68 Brigatinib Compared with Crizotinib and Alectinib in Patients with ALK-Positive Non-Small Cell Lung Cancer (NSCLC) with Brain Metastases at Diagnosis: A Cost-Effectiveness Analysis from the Perspective of the Brazilian Private Health ...
Jun 1, 2021, 00:00
10.1016/j.jval.2021.04.160
https://www.valueinhealthjournal.com/article/S1098-3015(21)00377-6/fulltext
Title :
PCN68 Brigatinib Compared with Crizotinib and Alectinib in Patients with ALK-Positive Non-Small Cell Lung Cancer (NSCLC) with Brain Metastases at Diagnosis: A Cost-Effectiveness Analysis from the Perspective of the Brazilian Private Health ...
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(21)00377-6&doi=10.1016/j.jval.2021.04.160
First page :
Section Title :
Open access? :
No
Section Order :
10738